Prempharm

Prempharm is a clinical-stage biotechnology company based in the United Kingdom that focuses on developing innovative treatments for neonatal conditions, particularly those affecting extremely premature infants. The company's lead program involves the development of a specialized oral formulation of propranolol for the prevention and treatment of Retinopathy of Prematurity (ROP), a condition that can lead to permanent vision loss. Prempharm leverages clinical research and academic partnerships to address unmet medical needs in the neonatal intensive care unit (NICU). By focusing on the repurposing and precise dosing of established molecules, the company aims to improve long-term outcomes for the most vulnerable patient populations. Their work is supported by clinical evidence from multi-center trials investigating the safety and efficacy of beta-blockers in neonatal eye disease. The company is dedicated to translating academic research into licensed pharmaceutical products for the neonatal market.